Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

Houston-based Moleculin Biotech now has four different oncology treatment currently in trials. Getty Images

A Houston-based biotech company has wrapped up enrollment for its most recent clinical trial of its cancer-fighting drug.

Moleculin Biotech Inc. (Nasdaq: MBRX) has launched its fourth ongoing trial — this time focusing on Cutaneous T-Cell Lymphoma, or CTCL, treatment. The company's other three trials include treatment for glioblastoma, an aggressive brain cancer, pancreatic cancer, one of the most virulent killers in oncology, and acute myeloid leukemia, or AML.

To treat these various types of cancers, Moleculin has a several drugs it's in preclinical or clinical trials testing — most biotech companies have only one they focus on. WP1220 is the drug that will be used in this trial for topical CTCL treatment of the cancer's resulting skin lesions.

"We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "especially one that may avoid significant unwanted side effects."

WP1220 is what's known as a p-STAT3 inhibitor. STAT3 is a transcription factor that encourages tumor development. Moleculin's technology directly attacks the tumor, but also quiets T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

"This proof of concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor," Klemp continues. "We are pleased with how quickly this trial reached full recruitment and we are hopeful to be able to announce results from this trial yet this year."

Klemp founded the company in 2007, and Moleculin went public in 2016. Now, with the company's four clinical trials, Moleculin is even closer to saving lives with its products.

"Notwithstanding the relatively rare nature of CTCL, we believe showing activity with one of our STAT3 inhibitors, within our WP1066 family of molecules, could be an indicator of both the value of p-STAT3 as a target and the potential for our drugs in other cancers where STAT3 is highly activated," Klemp says in the release.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.

From cryotherapy and NASA-inspired fitness to startup funding and biotech, this week's innovators to know are raising the bar on health tech and innovation. Courtesy photos

4 health-focused Houston innovators to know this week

Who's who

This week's innovators to know are focused on health and wellness, from a Houston-based cryotherapy franchise to the person behind funding medical device and digital health startups. We couldn't narrow these folks down to the usual three, so here are the four Houston innovators to know as we start the last week in February.

Juliana Garaizar, director of the Texas Medical Center Venture Fund

Courtesy of TMC

Juliana Garaizar has worked all around the world, and her international contacts and venture capital experience has landed her at the heart of the Texas Medical Center leading the TMC Venture Fund.

"I think TMC wants to be positioned as a strong competitor to the East and West Coasts as a point of entry for companies coming to the United States, but also for technology and commercializations from hospitals," she tells InnovationMap. "The fact that I'm already very connected to other countries — not only from the funding side but also from the research side, is really helpful."

Garaizar has her hands full running the $25 million nonprofit fund that invests around $2 million a year. Recipients, which all have a connection to TMC either through the accelerator or workspaces, receive a range between $250,000 to $500,000, and can go up to $1 million in a deal, Garaizar says. She is focused on securing deal flow for the fund before growing it more.

"In the long term, we would like to raise a bigger fun, around $100 million fund," she says. "We would need to make sure we have our deal flow ready for that, and a big part of that would be international deal flow."

Walter Klemp, chairman and CEO of Moleculin

Courtesy of Moleculin

It's pretty concerning to Walter Klemp that, while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he tells InnovationMap. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The company has three core technologies currently being tested with some success, but the most promising is called WP1066, which uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The active compound both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

Jay Sutaria, founder and lead trainer of Sutaria Training & Fitness

Courtesy of ST&F

Earthbound Houstonians have a chance to use NASA training equipment thanks to Jay Sutaria's company, Sutaria Training & Fitness.

"It's exclusive access to the equipment that is not available openly in Houston," Sutaria tells InnovationMap. "NASA is a reference for us to become better trainers."

Sutaria founded his company in 2011 while he was a student at the University of Houston, and the company now operates with two trainers. His clients include professional athletes such as D.J. Augustin (Orlando Magic, NBA); and Tim Frazier (New Orleans Pelicans, NBA), however, Sutaria and his team offer professional personal training services to any type of athlete.

Kyle Jones, COO of iCRYO

Courtesy of iCryo

Kyle Jones says he's always known he was destined for entrepreneurship, and when he came across the potential of cryotherapy while working at a physical therapist office, he knew it was a scalable business.

He opened his first location of iCRYO in League City in 2015. Now the company is

Jones says he used the location to work out the kinks of his business model, since he didn't really have much to model after. One thing that was most important to Jones, with his PT background, was safety of the patients. He cared about this more than making money, he says.

"I knew first and foremost the one thing that the cryotherapy space didn't have was a certification program, which is kind of terrifying to me," Jones tells InnovationMap. "Any therapy has some type of schooling or certification — massage therapy and acupuncture both have it. Cryotherapy even to date does not a certification to it."

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Houston biotech company aims to enhance oncology treatment of highly resistant cancers

Med tech

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

10+ can't-miss Houston business and innovation events for October

WHERE TO BE

From networking meetups to pitch competitions, October is lined with opportunities for Houston innovators.

Here's a roundup of events you won't want to miss out on so mark your calendars and register accordingly.

Note: This post might be updated to add more events.

Additionally, mark your calendars for November 8 for the annual Houston Innovation Awards.

October 6 — Texas Venture Crawl

Head over to the Ion for pre-panel networking, an engaging Ask-Me-Anything (AMA) investor panel, followed by a happy hour for networking. Panelists include Grace Chan, Principal at bp Ventures; Jason Ethier, Founder of Lambda Catalyzer; Alex Gras, Associate at Mercury Fund; and Billy Grandy, Chief Innovation Officer and Managing Partner at Softeq Venture Fund.

This event is Friday, October 6, from 5 to 8 pm at the Ion. Click here to register.

October 7 — Ideation Competition

The Pearland Innovation Hub is hosting it's first Ideation Competition. Participants will get an opportunity to have mentors guide them through Design Thinking and other methodologies to help generate ideas to solve local civic issues.

This event is Saturday, October 7, from 9:30 am to 3 pm at Pearland Innovation Hub. Click here to register.

October 11 — Emerging Tech: Revolutionizing the Industry Panel

From artificial intelligence and blockchain to virtual reality, this panel will explore the impact of these innovations on businesses and society. Whether you are a tech enthusiast, a professional in the industry, or simply curious about the future of technology, this event will have valuable networking opportunities.

This event is Wednesday, October 11, from 1 to 2 pm at HCC West Loop Campus. Click here to register.

October 13 — Web3, Blockchain, & Crypto...Oh My!

Expert speakers will unravel the mysteries of Web3, showcasing its potential to revolutionize industries like finance, gaming, and more. Learn about the power of Blockchain technology and how it ensures transparency, security, and trust in various sectors. Explore the endless possibilities of Cryptocurrencies and their impact on the global economy.

This event is Friday, October 13, at the Cannon. Click here to register.

October 16 — Health & MedTech Mingle

Pumps & Pipes is hosting a night of industry mingles occurring simultaneously at the Ion featuring FinTech, EdTech, Food Tech, and more. This month's featured speaker is Dr. Alan Lumsden, Chair of Cardiovascular Surgery and Chair of the DeBakey Heart & Vascular Center at Houston Methodist.

This event is Monday, October 16, at the Ion. Click here to register.

October 19 — UH Energy Symposium Series - The Future of Mobility Promises & Bottlenecks

The latest installment of UH Energy's Critical Issues in Energy Symposium Series tackles the obstacles facing a transition to a circular economy.

Panelists to include: Dave Mullaney – Principal, Rocky Mountain Institute; Varuna Singh – Deputy District Engineer TxDOT; Erika Myers – Executive Director, CharIN, e.V.; Matt Peterson – President and CEO, Los Angeles Cleantech Incubator; Catherine McCreight – Director of Transportation Planning, TxDOT; Funda Sahin – Associate Professor of Supply Chain Management, University of Houston (Moderator).

This event is Thursday, October 19, at the University of Houston. Click here to register.

October 25 — Houston Startup Ecosystem Summit

The Houston Startup Ecosystem Summit is an opportunity for innovators, entrepreneurs, and tech enthusiasts to come together and push the boundaries of what's possible. This event features a lineup of panelists, diverse breakout session tracks, and a competitive startup pitch showcase.

This event is Wednesday, October 25, at the Cannon. Click here to register.

October 25 — TMC Startup Symposium

The Symposium will include 1:1 time with subject matter experts, industry networking events, educational presentations, and thought leader panel discussions. The following topics will be covered: intellectual property, voice of customer, regulatory reimbursement, clinical commercialization strategy, angel investing, venture capital investing, and serial entrepreneurship. Startup registration is $250 for a ticket.

This event starts Wednesday, October 25, from 8 am to 5 pm at TMCi. Click here to register.

October 26 — Unleash the Power of AI and ChatGPT

Attendees will have the opportunity to interact with a panel of industry experts, and network with like-minded individuals. Whether you're a seasoned professional or just starting your AI journey, this event is designed to inspire and educate. Discover how AI is revolutionizing various industries and learn how to leverage its power to drive innovation in your own projects.

This event is Thursday, October 26, from 6 to 8:30 pm at the Cannon. Click here to register.

October 27 — SHINE: The Conference on Culture

Shine is a half day conference focused on the organizational structures of workplaces. Attendees can expect to hear from a range of speakers who will share their wisdom gained from industries, from breweries to public relations.

This event is Friday, October 27, from 8 am to 1 pm at Stages. Click here to register.

October 30-31 — Fuze

This energy conference is a must-attend event for executives, investors, and founders serious about solving the energy crisis and boosting company efficiency. Featuring keynotes, expert panels, tech showcases, and networking, Fuze has a variety of activities planned for energy industry professionals. Price of admission ranges from $299-$799.

This event starts on Monday, October 30, from 8 am to 7 pm at 713 Music Hall. Click here to register.

Houston school names digital education expert to newly created position

new to rice

Rice University is beefing up its digital education efforts with the hiring of an internationally known expert from Duke University.

Shawn Miller is set to join Rice on November 1 in the newly created position of associate provost for digital learning and strategy. Miller’s hiring culminates a nationwide executive search announced in May 2023 and led by C. Fred Higgs III, vice provost for academic affairs.

Rice explains that Miller “will be the key steward of Rice’s digital strategy — leveraging best practices already in place across the university as well as introducing new approaches and collaborations to be scaled.”

Miller comes to Rice from Duke, a North Carolina school where he most recently has been associate vice provost and chief of staff for learning innovation. Miller previously was Duke’s interim associate vice provost for digital education and innovation. And for six years, he directed Duke Learning Innovation, which he co-designed and launched. He began working for Duke in 2006 as an academic technology consultant.

Shawn Miller is set to join Rice on November 1 in the newly created position of associate provost for digital learning and strategy. Photo courtesy of Rice

Earlier, he led creation of the first learning management system for the University of Texas at El Paso. Miller holds bachelor’s and master’s degrees from UTEP.

“I’ve spent the better part of my career helping universities transform and change to better serve their students,” Miller says in a Rice news release. “I look forward to leveraging my skills to empower Rice’s community of scholars, researchers, and learners to transform themselves, their communities, and others through education.”

In the news release, Joshua Kim, director of online programs and strategy at Dartmouth College in New Hampshire, calls Miller “an internationally recognized leader in the digital learning and online education space.”

“His move to a new leadership role at Rice is a very significant development within our education innovation community,” says Kim.

Miller’s accomplishments at Duke include:

Setting up a digital publishing platform for learning
Shifting thousands of faculty and students from a legacy learning management system to a new digital system
Building a partnership with online education provider Coursera

“Shawn is a national leader in digital innovation and has a deep understanding of digital learning as well as proven experience in building a sustainable, long-term strategy for innovation and developing an integrated approach across the university,” says Amy Dittmar, a Rice provost who is executive vice president for academic affairs.

“I am excited to work with Shawn as he leads Rice to enhance digital education for current students,” Dittmar adds, “and look forward to seeing more professionals in Houston and around the world benefit from a Rice education as a result of his efforts.”

Initiatives spearheaded by Miller and other professionals in digital education have gained traction since the onset of the COVID-19 pandemic, which forced Rice and other colleges and universities to accelerate their embrace of virtual learning.

“The growing adoption of digital learning technologies continues to push education into uncharted areas,” according to an article published this March in the research journal Sustainability.

“While teachers must rethink what it means to provide a learning experience,” the article goes on to say, “higher education institutions must match their educational technology solutions to students’ demands. Digital learning is far superior to the conventional classroom paradigm in many ways for both teachers and students.”

The value of the global market for digital education is projected to jump from $1.2 billion in 2018 to $77.23 billion by 2028, driven in part by growing interest among colleges and universities in augmented reality (AR).

Houston-area schools make best universities list, tech nonprofit expands, and more trending news

INNOVATIONMAP EMAILS ARE AWESOME

Houston cancer-fighting biotech company introduces its 4th ongoing clinical trial

health report

5 Houston biotech companies taking health care to new levels